Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
This book dives into the financial side of cancer treatment, focusing on immunotherapy. It analyzes costs of new treatments, comparing them to traditional methods.Chapter 1 gives an economic overview of cancer immunotherapy, including cost analyses, funding, and global impact. Chapter 2 explores checkpoint inhibitor pricing and financial aid models. Chapter 3 breaks down CAR T-cell therapy expenses, while Chapter 4 examines cancer vaccine development costs.Chapters 5-11 cover various immunotherapies, discussing development costs, market adoption, and financial policies. Chapter 12 proposes strategies to lower costs and improve global access.Essential reading for healthcare financiers, policymakers, and those involved in cancer treatment, this book provides key insights into the financial implications of advanced cancer therapies.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
This book dives into the financial side of cancer treatment, focusing on immunotherapy. It analyzes costs of new treatments, comparing them to traditional methods.Chapter 1 gives an economic overview of cancer immunotherapy, including cost analyses, funding, and global impact. Chapter 2 explores checkpoint inhibitor pricing and financial aid models. Chapter 3 breaks down CAR T-cell therapy expenses, while Chapter 4 examines cancer vaccine development costs.Chapters 5-11 cover various immunotherapies, discussing development costs, market adoption, and financial policies. Chapter 12 proposes strategies to lower costs and improve global access.Essential reading for healthcare financiers, policymakers, and those involved in cancer treatment, this book provides key insights into the financial implications of advanced cancer therapies.